CJC-1295 (With DAC) Research Overview
Overview
CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that incorporates a Drug Affinity Complex designed to extend its systemic activity through reversible binding to circulating albumin. This modified peptide formulation has been extensively investigated in human clinical studies examining growth hormone physiology, endocrine signaling, and metabolic regulation.
The CJC-1295 molecule consists of a modified GHRH sequence with specific amino acid substitutions that confer resistance to enzymatic degradation. The DAC component further extends systemic exposure by facilitating reversible association with plasma albumin, which reduces renal clearance and maintains sustained receptor activation. The albumin-binding properties of the DAC component are based on the high concentration of albumin in plasma and its long half-life, which together provide a circulating reservoir for the peptide.
Human pharmacokinetic studies have reported prolonged circulating activity following administration of CJC-1295 with DAC, with measurable peptide concentrations persisting for extended periods compared with native GHRH or non-DAC formulations. Published pharmacodynamic investigations have demonstrated sustained elevations in circulating growth hormone and insulin-like growth factor-1 (IGF-1) under controlled study conditions.
The extended pharmacokinetic profile of CJC-1295 with DAC has made it a valuable research tool for investigating the physiological consequences of sustained GHRH receptor stimulation. Investigations have examined its effects on growth hormone pulsatility, IGF-1 production, and downstream endocrine and metabolic pathways. Studies have reported that sustained GHRH receptor activation may lead to different patterns of growth hormone secretion compared with pulsatile stimulation, which is the physiological pattern of growth hormone release.
The clinical research literature includes multiple human studies examining its effects on growth hormone secretion, IGF-1 production, body composition, and metabolic endpoints. Published findings have demonstrated significant increases in circulating growth hormone and IGF-1 under controlled study conditions, with effects sustained over the duration of the evaluation period.
Key Scientific Characteristics
Synthetic GHRH analog with modified amino acid structure
Formulated with a Drug Affinity Complex (DAC) for prolonged systemic activity
Reversibly associates with circulating albumin to extend peptide half-life
Demonstrates sustained GHRH receptor activation compared with non-DAC formulations
Human pharmacokinetic studies have reported extended circulating activity under evaluated conditions
Investigated in laboratory and human clinical studies of growth hormone physiology
Not approved by the U.S. Food and Drug Administration for therapeutic use
Research Notes
Published clinical research has demonstrated that CJC-1295 with DAC produces sustained elevations in circulating growth hormone and IGF-1 under controlled study conditions. The extended pharmacokinetic profile is attributed to the DAC component, which reduces clearance through reversible albumin binding and maintains receptor occupancy over an extended period.
The DAC formulation continues to be investigated for its effects on growth hormone dynamics, endocrine signaling, and related physiological processes. Additional long-term studies are needed to fully characterize its pharmacological properties, safety profile, and biological effects across different research populations and study designs.
